ESTRO 2025 - Abstract Book

S1964

Clinical - Urology

ESTRO 2025

Early trial results suggest MR/spacer-facilitated NV-SAbR mitigates QoL impacts of PCa RT, with limitations of multiple comparisons. Determining the clinical magnitude of benefit may depend on dose and requires continued longitudinal assessment as planned, especially for sexual function. Funding: Boston Scientific

Keywords: Prostate, sexual function, spacer, SabR

References: 1. University of Texas Southwestern. (n.d.). POTEN-C Trial Radiotherapy Details. Accessed Nov 16 2024: https://www.utsouthwestern.edu/departments/radiation-oncology/research/clinical/poten-c/

1651

Digital Poster Stereotactic body radiotherapy for localized kidney cancer compared with standard surgery within a Young Academic Urologists Working group database Michele Aquilano 1 , Giulio Francolini 2 , Vanessa Di Cataldo 2 , Riccardo Campi 3 , Riccardo Bertolo 4 , Carlotta Palumbo 5 , Stijn Muselaers 6 , Savio Domenico Pandolfo 7 , Daniele Amparore 8 , Nicola Pavan 9 , Chiara Ciccarese 10 , Laura Marandino 11 , Selcuk Erdem 12 , Zhenje Wu 13 , Giuseppe Rosiello 14 , Gopal Sharma 15 , Gaelle Margue 16 , Michele Marchioni 17 , Pietro Diana 18 , Umberto Carbonara 19 , Pietro Garlatti 2 , Laura Masi 20 , Raffaella Doro 20 , Niccolò Bertini 2 , Lorenzo Livi 2 1 CyberKnife Center, Istituto Fiorentino di Cura ed Assistenza (IFCA), Florence, Italy. 2 Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy. 3 Unit of Urological Robotic Surgery and Renal Transplantation, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy. 4 Department of Urology, Borgo Trento Hospital, University of Verona, Verona, Italy. 5 Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy. 6 Department of Urology, Radboud University Medical Center,, Nijmegen, Netherlands. 7 Department of Urology, University of L' Aquila, L' Aquila, Italy. 8 Division of Urology Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy. 9 Department of precision medicine in medical, surgical and critical care, University of Palermo, Palermo, Italy. 10 Department of Medical Oncology, Università Cattolica del Sacro Cuore Fondazione Policlinico A.Gemelli IRCCS, Rome, Italy. 11 Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, United Kingdom. 12 Department of Urologic Oncology, Istanbul University, Florence, Turkey. 13 Department of Urology, Changhai hospital, Naval medical University,, Shangai, China. 14 Department of Urology and Division of Experimental Oncology,, Urological Research institute san Raffaele scientific institute, Milan, Italy. 15 Urologic oncology, Medanta Hospital, Ur, Gurgaon Haryan, India. 16 Department of Urology, Bordeaux University Hospital,, Bordeaux, France. 17 Department of Medical oral and biotechnological science "G.D'annunzio", University of Chieti and Pescara, Chieti, Italy. 18 Department of Urology, Fundació Puigvert, Autonomous University of Barcelona,, Barcelona, Spain. 19 Division of Urology Department of surgery, Santa Maria Hospital, Bari, Italy. 20 Department of Medical Physics and Radiation Oncology, Istituto Fiorentino di Cura ed Assistenza, Florence, Italy Purpose/Objective: Stereotactic body radiotherapy (SBRT) has been recognized as an option for selected non metastatic primary renal cell carcinomas (RCCs) [Siva 2024]. In order to standardize treatments it’s necessary defining the SBRT selection criteria. The aim of this study is to evaluate if critical issues are complementary between surgery and SBRT. Surgical troubles, e.g. proximity to renal pelvis or blood vessels are not an issue for SBRT. Conversely, patients eligible for nephron sparing surgery could be challenging for SBRT due to proximity of organs at risk (OAR), e.g bowel or duodenum. The Young Academic Urologists (YAU) working group RCC started to retrospectively evaluate SBRT feasibility in patients included in a multi institutional surgical database.

Material/Methods: